Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Part of paid clinical trials in Atlanta, Georgia.
- Sponsor
- Emory University
- Study ID
- NCT05834478
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Opioid Use
- Opioid Use Disorder
- Withdrawal Symptoms
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Transcutaneous Cervical Vagal Nerve Stimulation — DEVICEParticipants will receive stimulation of the vagus nerve with the non-invasive transcutaneous cervical Vagal Nerve Stimulation (tcVNS), which does not require surgery or implantation, and electrically stimulates the vagus nerve as it passes through the neck, dampening the sympathetic nervous system and modulating brain regions to a single side of the neck with the GammaCore device. Participants will be trained on self-stimulation and from days 1-7 patients undergo four times daily self-stimulation with tcVNS first for two minutes on one side, followed by a one-minute pause, then two minutes on the same side. The intensity of the stimulus (i.e. the current amplitude) will be adjusted by the user, to the maximum tolerable level without causing excessive pain \[typically 10-30 V and 60milliamperes (mA) (peak)\], with an alternating current (AC) signal consisting of five 5 kilohertz (kHz) pulses 200 microseconds in duration, repeating at a rate of 25 Hz (about once every 40 milliseconds).
- Sham Stimulation — DEVICEParticipants will have the same procedures as with the tcVNS but will instead receive a device that appears identical to the active tcVNS device in look, weight, visual and audible feedback, and also in user controls. The Sham device looks and sounds like an active device but does not deliver an electric current.
- [F-18]Fallypride — DRUG\[F-18\]Fallypride is a radioactive material. Each patient will have two \[F-18\]Fallypride PET scans. For each scan \[F-18\]Fallypride will be injected as an intravenous bolus. The radiation dose to body organs in this study is well within the Food and Drug Administration (FDA) national guidelines for radiation exposure for human research studies and less than the total amount that is permitted for research studies in one year.
Study Details
This study is being done to answer the question: what is the effect of Vagal Nerve Stimulation (VNS) dosing on opioid withdrawal responses in individuals with a history of Opioid Use Disorders (OUDs)? Eligible participants will be in the study for one week in an inpatient research hospital stay, have an MRI scan, and have a follow-up call 1-3 months after their inpatient stay. Participants will complete several psychiatric questionnaires/interviews, physiological monitoring with several devices, brain imaging, and VNS testing.
Key Dates
- Start date
- Feb 20, 2024
- Status verified
- Mar 2026
- Primary completion
- Feb 28, 2027
- Completion
- Apr 30, 2027
Study Design
- Enrollment
- 103 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Transcutaneous Cervical Vagal Nerve Stimulation DeviceStimulation with the tcVNS
- Sham Comparator: Sham Stimulation DeviceStimulation with the sham device.
Primary Outcome Measure
Change in Peak Subjective Opiate Withdrawal Scale (SOWS) Score [ Time Frame: Day 2, Day 3 ]
Central Contacts
- James D Bremner, MD404-712-9569
Locations (6)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| 12 Executive Park Drive | Atlanta | Georgia | 30329 | - |
| Emory University | Atlanta | Georgia | 30329 | - |
| Emory University Clinical Research Network | Atlanta | Georgia | 30322 | - |
| Georgia Institute of Technology | Atlanta | Georgia | 30332 | - |
| Health Sciences Research Building | Atlanta | Georgia | 30322 | - |
| Rollins School of Public Health | Atlanta | Georgia | 30322 | - |
Find similar trials in Atlanta, GA
By condition
By specialty
Related Studies
- Rural Expanded Access to OUD Care & Linkage Using Toxicologists for Telehealth Initiated TreatmentRecruiting · Emory University · Atlanta, Georgia
- Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug UseRecruiting · Elana Rosenthal · Washington D.C., District of Columbia
- Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3)Not Yet Recruiting · University of Georgia · Colbert, Georgia
- Houston Emergency Opioid Engagement SystemPHASE4 · Enrolling By Invitation · The University of Texas Health Science Center, Houston · Houston, Texas